Prof. Nicolaas Lumen
(28 June 2017)
The ideal biomarker should have a high accuracy and a high negative predictive value. This will allow to only find those cancers that will affect the life expectancy of the patient. SelectMDx is a biomarker with a negative predictive value of 98% for tumours with a Gleason score of more than 7. There is thus a 2% risk of missing these type of tumours when the SelectMDx test is negative. For tumours with a Gleason score of 8 and more, the risk of missing these tumours with the SelectMDx test is almost 0% (negative predictive value of 99.6%).